Arizona Clinical Research Center | Tucson, AZ

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), p...

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Ph...

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemothera...

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in partic...

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol inv...

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology...

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patien...

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in...